AL AMYLOIDOSIS
Clinical trials for AL AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new AL AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for AL AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
Disease control Not yet recruitingThis phase 2 trial is testing an investigational drug called QLS4131 in people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs and cause damage. QLS4131 is a trispecific antibody designed to target and eliminate the plasma cells produci…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug aims to shrink rare protein clumps in early trial
Disease control Not yet recruitingThis early study tests whether the drug CAEL-101/anselamimab can bind to and shrink abnormal protein deposits (amyloid) in people with AL amyloidoma. Five adults with measurable amyloid deposits will receive the drug and be monitored for up to 72 weeks. The goal is to see if the …
Matched conditions: AL AMYLOIDOSIS
Phase: EARLY_PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New scan spots hidden organ damage before symptoms start
Diagnosis Not yet recruitingThis study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole…
Matched conditions: AL AMYLOIDOSIS
Phase: NA • Sponsor: University of Zurich • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC